Puma Biotechnology, Inc. announced that the FDA has accepted for review the New Drug Application (NDA) for its lead product...
Puma Biotechnology has submitted its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for PB 272 (neratinib). The...
Relief of moderate to severe pain in all painful conditions where an alert patient is desired, e.g. sciatica, osteoarthritis, chronic rheumatoid arthritis, arthritis of the spine, peripheral vascular disease, post hepatic neuralgia, Paget's disease, malignant disease and post operative pain. Also used as an anti-tussive.
• As symptomatic treatment for allergic conditions of the upper respiratory tract and skin including allergic rhinitis, urticaria and anaphylactic reactions to drugs and foreign proteins. • As an antiemetic. For short term use: • Treatment of insomnia in adults. • As a paediatric sedative.
PhaseBio Pharmaceuticals announced interim results from REVERSE-IT (Rapid and SustainEd ReVERSal of TicagrElor – Intervention Trial) ongoing pivotal Phase III trial of PB 2452 (bentracimab) studying the reversal of the antiplatelet effects of ticagrelor with bentracimab in patients who present with urgent surgery or an invasive procedure or experiencing uncontrolled major or life-threatening bleeding.
Peripheral-blood (PB) and bone marrow (BM) are both widely used in hematopoietic stem cell transplantation (HSCT). However, it is unclear whether PB or BM produces a more satisfactory outcome in haploidentical HSCT...
Amylyx Pharmaceuticals announced that the FDA has extended the review timeline of the New Drug Application (NDA) for AMX 0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO; also known as ursodoxicoltaurine]) for the treatment of amyotrophic lateral sclerosis (ALS).
Puma Biotechnology, Inc. announced top line results from the Phase II clinical trial of Puma's investigational drug PB 272 (neratinib)...
Spinal muscular atrophy (SMA) is caused by insufficient levels of survival motor neuron (SMN) protein. Recently, we found that sodium 4-phenylbutyrate (PB), a well-tolerated FDA approved drug, enhances SMN gene expression in vitro.
For the treatment of mild to moderate pain, anti-pyretic and post immunisation pyrexia.